Infliximab

Details

Files

Generic Name:

Infliximab

Project Status:

Complete

Therapeutic Area:

Crohn’s disease and Ulcerative Colitis

Manufacturer:

Hospira HealthCare Corporation, a Pfizer Company

Call for patient/clinician input open:

March 11, 2016

Brand Name:

Inflectra (Subsequent Entry Biologic)

Project Line:

Reimbursement Review

Project Number:

SE0483-000

Call for patient/clinician input closed:

May 2, 2016

Submission Type:

Initial

Indications:

Crohn’s disease and Ulcerative Colitis

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

October 25, 2016

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Patient Group Input Submissions View PDF

Subsequent Entry Biologic Review Report View PDF

Last Updated : March 11, 2016